299 related articles for article (PubMed ID: 34195877)
21. Biofluid diagnostics by FTIR spectroscopy: A platform technology for cancer detection.
Sala A; Anderson DJ; Brennan PM; Butler HJ; Cameron JM; Jenkinson MD; Rinaldi C; Theakstone AG; Baker MJ
Cancer Lett; 2020 May; 477():122-130. PubMed ID: 32112901
[TBL] [Abstract][Full Text] [Related]
22. Potential risk factors of ovarian cancer and analysis of CA125, a biomarker used for its monitoring and diagnosis.
Mansha M; Gill A; Thomson PC
Mol Biol Rep; 2019 Jun; 46(3):3325-3332. PubMed ID: 31006098
[TBL] [Abstract][Full Text] [Related]
23. Clinical Value of Serum HE4, CA125, CA72-4, and ROMA Index for Diagnosis of Ovarian Cancer and Prediction of Postoperative Recurrence.
Wang Q; Wu Y; Zhang H; Yang K; Tong Y; Chen L; Zhou Q; Guan S
Clin Lab; 2019 Apr; 65(4):. PubMed ID: 30969083
[TBL] [Abstract][Full Text] [Related]
24. Postoperative human epididymis protein 4 predicts primary therapy outcome in advanced epithelial ovarian cancer.
Vallius T; Hynninen J; Auranen A; Matomäki J; Oksa S; Roering P; Grènman S
Tumour Biol; 2017 Feb; 39(2):1010428317691189. PubMed ID: 28218038
[TBL] [Abstract][Full Text] [Related]
25. Combination of CA125 and RECAF biomarkers for early detection of ovarian cancer.
Tcherkassova J; Abramovich C; Moro R; Chen C; Schmit R; Gerber A; Moro R
Tumour Biol; 2011 Aug; 32(4):831-8. PubMed ID: 21625941
[TBL] [Abstract][Full Text] [Related]
26. Folate-receptor 1 (FOLR1) protein is elevated in the serum of ovarian cancer patients.
Leung F; Dimitromanolakis A; Kobayashi H; Diamandis EP; Kulasingam V
Clin Biochem; 2013 Oct; 46(15):1462-8. PubMed ID: 23528302
[TBL] [Abstract][Full Text] [Related]
27. [The Advancement of Attenuated Total Reflection Fourier Transform Infrared Technology in Clinical Application].
Zhang XQ; Sun XL; Pan QH; Zhang YF; Xu Z; Guo XY
Guang Pu Xue Yu Guang Pu Fen Xi; 2017 Feb; 37(2):408-11. PubMed ID: 30265462
[TBL] [Abstract][Full Text] [Related]
28. No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting.
Jacob F; Meier M; Caduff R; Goldstein D; Pochechueva T; Hacker N; Fink D; Heinzelmann-Schwarz V
Gynecol Oncol; 2011 Jun; 121(3):487-91. PubMed ID: 21420727
[TBL] [Abstract][Full Text] [Related]
29. Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer.
Clarke CH; Yip C; Badgwell D; Fung ET; Coombes KR; Zhang Z; Lu KH; Bast RC
Gynecol Oncol; 2011 Sep; 122(3):548-53. PubMed ID: 21708402
[TBL] [Abstract][Full Text] [Related]
30. The value of 18F-FDG PET/CT imaging combined with detection of CA125 and HE4 in the diagnosis of recurrence and metastasis of ovarian cancer.
Sun J; Cui XW; Li YS; Wang SY; Yin Q; Wang XN; Gu L
Eur Rev Med Pharmacol Sci; 2020 Jul; 24(13):7276-7283. PubMed ID: 32706065
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic test for ovarian cancer composed of ovarian cancer symptom index, menopausal status and ovarian cancer antigen CA125.
Macuks R; Baidekalna I; Donina S
Eur J Gynaecol Oncol; 2011; 32(3):286-8. PubMed ID: 21797118
[TBL] [Abstract][Full Text] [Related]
32. Validation of a Novel Biomarker Panel for the Detection of Ovarian Cancer.
Leung F; Bernardini MQ; Brown MD; Zheng Y; Molina R; Bast RC; Davis G; Serra S; Diamandis EP; Kulasingam V
Cancer Epidemiol Biomarkers Prev; 2016 Sep; 25(9):1333-40. PubMed ID: 27448593
[TBL] [Abstract][Full Text] [Related]
33. New tumor markers: CA125 and beyond.
Bast RC; Badgwell D; Lu Z; Marquez R; Rosen D; Liu J; Baggerly KA; Atkinson EN; Skates S; Zhang Z; Lokshin A; Menon U; Jacobs I; Lu K
Int J Gynecol Cancer; 2005; 15 Suppl 3():274-81. PubMed ID: 16343244
[TBL] [Abstract][Full Text] [Related]
34. Postprandial increase in serum CA125 as a surrogate biomarker for early diagnosis of ovarian cancer.
Gu Z; He Y; Zhang Y; Chen M; Song K; Huang Y; Li Q; Di W
J Transl Med; 2018 May; 16(1):114. PubMed ID: 29716620
[TBL] [Abstract][Full Text] [Related]
35. Optical biomarker analysis for renal cell carcinoma obtained from preoperative and postoperative patients using ATR-FTIR spectroscopy.
Tian Y; Fan X; Chen K; Chen X; Peng W; Wang L; Wang F
Spectrochim Acta A Mol Biomol Spectrosc; 2024 Oct; 318():124426. PubMed ID: 38763020
[TBL] [Abstract][Full Text] [Related]
36. Spectral classification for diagnosis involving numerous pathologies in a complex clinical setting: A neuro-oncology example.
Bury D; Morais CLM; Paraskevaidi M; Ashton KM; Dawson TP; Martin FL
Spectrochim Acta A Mol Biomol Spectrosc; 2019 Jan; 206():89-96. PubMed ID: 30086451
[TBL] [Abstract][Full Text] [Related]
37. Diagnostic accuracy of CA125 and HE4 in ovarian carcinoma patients and the effect of confounders on their serum levels.
Ahmed AA; Abdou AM
Curr Probl Cancer; 2019 Oct; 43(5):450-460. PubMed ID: 30670303
[TBL] [Abstract][Full Text] [Related]
38. The utility of human epididymal protein 4, cancer antigen 125, and risk for malignancy algorithm in ovarian cancer and endometriosis.
Kadija S; Stefanovic A; Jeremic K; Radojevic MM; Nikolic L; Markovic I; Atanackovic J
Int J Gynecol Cancer; 2012 Feb; 22(2):238-44. PubMed ID: 22214964
[TBL] [Abstract][Full Text] [Related]
39. Microvesicles as potential ovarian cancer biomarkers.
Giusti I; D'Ascenzo S; Dolo V
Biomed Res Int; 2013; 2013():703048. PubMed ID: 23484144
[TBL] [Abstract][Full Text] [Related]
40. A Targeted Mass Spectrometry Strategy for Developing Proteomic Biomarkers: A Case Study of Epithelial Ovarian Cancer.
Hüttenhain R; Choi M; Martin de la Fuente L; Oehl K; Chang CY; Zimmermann AK; Malander S; Olsson H; Surinova S; Clough T; Heinzelmann-Schwarz V; Wild PJ; Dinulescu DM; Niméus E; Vitek O; Aebersold R
Mol Cell Proteomics; 2019 Sep; 18(9):1836-1850. PubMed ID: 31289117
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]